VC trio debuts seed fund; Takeda cuts early gene therapy work; Biogen’s new face of BD; Biotech investors get hands on; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
By now, most, if not all, of you will have heard about the exciting news that Endpoints has joined the Financial Times family. Thank you for all of your support over the years — and now, onto greater things!
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.